HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer
HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer
复制标题
DOI：
10.1023/a:1011151505425
复制
发表时间：
2001-01-01
影响因子：
50.5
通讯作者：
Tagliabue, E
中科院分区：
文献类型：
--
作者：
Ménard, S;Casalini, P;Tagliabue, E
迄今为止，HER2状态评估的标准化较差，无法对不同肿瘤中的过表达率进行可靠的比较。然而，标准化的方法已被引入最近这些分析，并已确定的频率为51%，44%，26%和25%的肾母细胞瘤，膀胱癌，胰腺癌和乳腺癌，分别。其他测试的肿瘤的频率低于20%。在某些肿瘤类型中，该频率大于基因扩增数据预测的频率，这可能表明由于基因失调而不是基因扩增导致的过表达。一个大的回顾性系列乳腺癌的分析表明，HER2阳性和其他一些预后标志物之间的关联。总之，这些变量确定了一个预后不良和术后早期复发的肿瘤子集。HER2表达相对稳定，原发性和转移性病变的HER2状态之间的一致性为95%。然而，对侧肿瘤在HER2状态方面不受限制。初步数据表明，激素受体阳性肿瘤的HER2状态可能会根据月经周期而波动。预计新出现的大量HER2状态的标准化数据将有助于阐明HER2在肿瘤进展中的作用。
To date, poor standardization in HER2 status evaluation has precluded reliable comparison of overexpression rates in different tumors. However, standardized methodologies have been introduced recently for these analyses, and have identified frequencies of 51%, 44%, 26% and 25% in Wilm's tumor, bladder, pancreatic and breast carcinoma, respectively. Other tumors tested had frequencies below 20%. The frequency was greater than that predicted by gene amplification data in some tumor types, which may indicate overexpression due to gene deregulation, rather than gene amplification. Analysis of a large retrospective series of breast carcinomas demonstrated an association between HER2 positivity and a number of other prognostic markers. Together, these variables identify a subset of tumors with poor prognosis and early relapse post-surgery. HER2 expression is relatively stable, with 95% concordance between the HER2 status of primary and metastatic lesions. However, contralateral tumors are unrestricted with regard to HER2 status. Preliminary data indicate that the HER2 status of a hormone receptor-positive tumor may fluctuate according to the menstrual cycle. It is anticipated that the emerging wealth of standardized data for HER2 status will help to elucidate the role of HER2 in tumor progression.